Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality.

Science bulletin - 15 May 2024

Li Shijie, Juengpanich Sarun, Topatana Win, Xie Tianao, Hou Lidan, Zhu Yiyuan, Chen Jiadong, Shan Yukai, Han Yina, Lu Ziyi, Chen Tianen, Topatana Charlie, Zhang Bin, Cao Jiasheng, Hu Jiahao, Yan Jiafei, Chen Yingxin, Gu Zhen, Yu Jicheng, Cai Xiujun, Chen Mingyu

Abstract excerpt

Adavosertib (ADA) is a WEE1 inhibitor that exhibits a synthetic lethal effect on p53-mutated gallbladder cancer (GBC). However, drug resistance due to DNA damage response compensation pathways and high toxicity limits further applications. Herein, estrone-targeted ADA-encapsulated metal-organic frameworks (ADA@MOF-EPL) for GBC synthetic lethal treatment by inducing conditional factors are developed. The high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gallbladder Neoplasms
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyrimidinones

Share to Reactive Oxygen Species

Share to Synthetic Lethal Mutations

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38519399
DOI: 10.1016/j.scib.2024.02.039

Genes

ADA
WEE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality.PMID 38519399Read ↗

Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer.Semantic proximity Read ↗

Sequential Ubiquitination and Phosphorylation Epigenetics Reshaping by MG132‐Loaded Fe‐MOF Disarms Treatment Resistance to Repulse Metastatic Colorectal CancerSemantic proximity Read ↗

Synthetically lethal nanoparticles for treatment of endometrial cancer.Semantic proximity Read ↗

Ligand conjugated lipid-based nanocarriers for cancer theranosticsSemantic proximity Read ↗

A super-assembled synergistically nanoplatform AP@ZIF-8 Pt for hepatocarcinoma therapySemantic proximity Read ↗

Harnessing DNA Tetrahedral Nanoparticles: A Novel Strategy for Co- delivery of OTUD6B siRNA and DOX Against TNBC Growth and ProgressionSemantic proximity Read ↗

Resiquimod-encapsulated MOF525 for Sustained Immunostimulant Release and Synergistic Photodynamic– Immunotherapy in Colorectal CancerSemantic proximity Read ↗

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian CancersSemantic proximity Read ↗

Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework NanoparticlesSemantic proximity Read ↗

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.Semantic proximity Read ↗

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Semantic proximity Read ↗

Switching Apoptosis to Ferroptosis: Metal–Organic Network for High-Efficiency Anticancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.